Why Micron Stock Sank Today

The Motley Fool
Updated
Mitrade
coverImg
Source: Shutterstock

Micron (NASDAQ: MU) stock got hit with big sell-offs in Tuesday's trading. The memory chip specialist's share price ended the daily session down 4.2%. Meanwhile, the S&P 500 index fell 0.3%, and the Nasdaq Composite fell 0.1%.

Micron's valuation is slipping today in conjunction with a new report published by Edgewater Research. Edgewater thinks that the demand outlook for Micron's NAND and DRAM chips will be weaker than previously anticipated, and investors are responding to the analysis by moving out of the stock.

Will the memory chip market be weaker than expected next year?

Edgewater's recent research note brought bearish analysis for Micron on two separate but related fronts. For starters, the analysis suggests that demand for NAND memory solutions is weakening among original equipment manufacturers and cloud service providers. Demand for NAND solutions among data center customers is expected to come in somewhere between flat and a slight increase next year.

Making matters worse, Edgewater's analysts are also seeing pricing forecasts for NAND across all major segments come down. DRAM prices are also projected to come down. As opposed to the supply-constrained outlook some analysts were forecasting for 2025, Edgewater is seeing more than enough supply to meet demand and downward pricing pressures.

What comes next for Micron?

Micron stock has seen big swings this year as investors have attempted to weigh how much of a near-term benefit the company will see from artificial intelligence (AI) trends. On the heels of today's pullback, the company is now valued at less than 12 times this year's expected earnings.

MU PE Ratio (Forward) Chart

MU PE Ratio (Forward) data by YCharts.

After posting solid sales growth and swinging to a strong profit last quarter, the stock looks cheap by some metrics. But as the recent report from Edgewater highlights, performance in the memory chip industry is heavily shaped by cyclical shifts. With some signs suggesting that demand and pricing for key memory solutions will be weaker than expected next year, investors could continue to take a cautious approach to Micron stock. On the other hand, Edgewater also noted that the outlook on demand and pricing is highly fluid, and it remains to be seen how demand among enterprise customers will shape the industry backdrop.

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
India’s economy is tumbling, and it might take whole world down with itIndia’s economy is spiraling. The rupee is sinking like a stone, dragging with it a mix of trade deficits, shrinking capital inflows, and uncertainty. The country’s economy has quickly become so important that if it plummets, the global economy will be at stake.
Author  Cryptopolitan
39 mins ago
India’s economy is spiraling. The rupee is sinking like a stone, dragging with it a mix of trade deficits, shrinking capital inflows, and uncertainty. The country’s economy has quickly become so important that if it plummets, the global economy will be at stake.
placeholder
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.
Author  The Motley Fool
40 mins ago
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.
placeholder
Novo Nordisk Sees Retail Buying Despite Wall Street CutsShares of leading weight-loss drugmaker Novo Nordisk (NVO.US) plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.
Author  Mitrade
5 hours ago
Shares of leading weight-loss drugmaker Novo Nordisk (NVO.US) plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.
placeholder
The Year of Concentration, Crypto, ChinaWhy 2024 was such a good year for investors, and the concerns they have about valuations and market concentration as they look ahead to 2025.
Author  The Motley Fool
7 hours ago
Why 2024 was such a good year for investors, and the concerns they have about valuations and market concentration as they look ahead to 2025.
placeholder
Prediction: This Energy Stock Will Deliver Substantial Market-Beating ReturnsExplore the exciting world of Chart Industries (NYSE: GTLS) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Author  The Motley Fool
7 hours ago
Explore the exciting world of Chart Industries (NYSE: GTLS) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!